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Background: In COVID 19 related lung disease, which is a leading cause of death from 
this disease, cytokines like tumor necrosis factor-alpha (TNF alpha) may be pivotal in the 
pathogenesis. TNF alpha reduces fluid absorption due to impairment of sodium and 
chloride transport required for building an osmotic gradient across epithelial cells, which 
in the airways maintains airway surface liquid helping to keep airways open and enabling 
bacterial clearance and aids water absorption from the alveolar spaces. TNF alpha can, 
through Rho-kinase, disintegrate the endothelial and epithelial cytoskeleton, and thus 
break up intercellular tight junctional proteins, breaching the intercellular barrier, which 
prevents flooding of the interstitial and alveolar spaces with fluid.
Hypotheses: (1) Preservation and restoration of airway and alveolar epithelial sodium 
and chloride transport and the cytoskeleton dependent integrity of the cell barriers within 
the lung can prevent and treat COVID 19 lung disease. (2) TNF alpha is the key mediator 
of pulmonary edema in COVID 19 lung disease.
Confirmation of hypothesis and implications: The role of a reduction in the function 
of epithelial sodium and chloride transport could with regards to chloride transport be 
tested by analysis of chloride levels in exhaled breath condensate and levels correlated 
with TNF alpha concentrations. Reduced levels would indicate a reduction of the function 
of the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel and 
a correlation with TNF alpha levels indicative of its involvement. Anti-TNF alpha treatment 
with antibodies is already available and needs to be tested in randomized controlled trials 
of COVID 19 lung disease. TNF alpha levels could also be reduced by statins, aspirin, 
and curcumin. Chloride transport could be  facilitated by CFTR activators, including 
curcumin and phosphodiesterase-5 inhibitors. Sodium and chloride transport could 
be further regulated to prevent accumulation of alveolar fluid by use of Na(+)/K(+)/2Cl(−) 
cotransporter type 1 inhibitors, which have been associated with improved outcome in 
adults ventilated for acute respiratory distress syndrome (ARDS) in randomized controlled 
trials. Primary prevention of coronavirus infection and TNF alpha release in response to 
it could be  improved by induction of antimicrobial peptides LL-37 and human beta 
defensin-2 and reduction of TNF alpha production by vitamin D prophylaxis for the 
population as a whole.
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INTRODUCTION
Lessons From the Radiological Features of 
COVID 19 Lung Disease
A chest computed tomographic (CT) study in Wuhan, China 
of 131 COVID 19 patients showed that changes found were 
mainly bilateral peripheral ground glass opacities (GGO) 
combined with or without co-existing consolidations (total of 
62% of cases; Li et  al., 2020).
Another study of 73 cases demonstrated in the majority 
(n  =  43) single or multiple GGOs in the periphery of the 
lungs. In the 21 patients with more severe clinical disease, 
extensive GGO and pulmonary consolidations were found in 
16/21 and 5/21 cases, respectively. The authors commented 
that the changes were similar to those found in influenza 
H1N1 virus pneumonia (Liu et  al., 2020).
A pictorial review of chest CT manifestations of COVID 
19 lung disease summarized that the most common 
features is GGO, which in COVID 19 patients are commonly 
in a peripheral lung and subpleural distribution in up to 
98% of patients. This is followed by consolidations, which 
are increasingly common with further progression of the 
disease (Ye et  al., 2020).
Lessons From Autopsy Results
The first detailed autopsy result of a 50-year-old man in 
Beijing with COVID 19 associated acute respiratory distress 
syndrome (ARDS), demonstrated at day 14 of illness, 
unequal appearances of both lungs with “bilateral diffuse 
alveolar damage” with “cellular fibromyxoid exudates” and 
features of pulmonary edema with formation of “hyaline 
membranes” (Xu et  al., 2020).
In a study of 10 fatal cases, which was done in Sao 
Paulo, Brazil using ultrasound-based minimally invasive 
autopsies histological samples from lungs revealed “diffuse 
alveolar damage with intense epithelial viral cytopathic effects 
involving alveolar and small airway epithelium and little 
lymphocytic infiltration.” “A variable number of small fibrinous 
thrombi in small pulmonary arterioles in areas of both 
damaged and more preserved lung parenchyma” was noted 
in eight cases (Dolhnikoff et  al., 2020). A subsequent 
autopsy study of seven patients revealed disseminated 
pulmonary vascular thrombosis more widespread than in 
influenza (Ackermann et  al., 2020).
Immunopathological Features of Severe 
COVID 19 Lung Disease
Twenty one patients with COVID-19 were analyzed with regard 
to features of their immunological response retrospectively. 
Compared with moderate cases, severe cases had significantly 
elevated concentrations of TNF alpha, interleukin (IL)-2R, IL-6, 
and IL-10 (Chen et  al., 2020b).
The action of TNF alpha can explain the multi-organ failure 
found in severe COVID 19 disease. It is a vasoconstriction 
causing cytokine which can cause ischemia in all organ systems 
(Vila and Salaices, 2005), including heart, liver, and kidneys as 
seen in fatal cases (Chen et  al., 2020a), thus responsible for 
widespread ischemic organ damage in multiple organs. Radiological 
and autopsy findings are consistent with an inflammatory process 
causing pulmonary interstitial and alveolar fluid accumulation.
The Hypotheses
 • Preservation and restoration of airway and alveolar epithelial 
sodium and chloride transport and the cytoskeleton dependent 
integrity of the cell barriers within the lung can prevent 
and treat COVID 19 lung disease.
 • TNF alpha is the key mediator of pulmonary edema in 
COVID 19 lung disease.
EXPLANATION OF THE HYPOTHESES
The Role of Epithelial and Endothelial 
Sodium and Chloride Transport in 
Pulmonary Airway Liquid Film Depth and 
Alveolar Fluid Clearance
The depth of the airway liquid film is dependent on uptake 
of sodium through epithelial sodium channels (ENaC) and 
secretion of chloride through the cystic fibrosis transmembrane 
conductance regulator (CFTR) chloride channel in airway 
epithelial cells. In genetic mutations, inactivating ENaC (systemic 
pseudohypoaldosteronism) or CFTR (cystic fibrosis), there are 
tenacious dehydrated airway secretions causing lung disease 
and this is the clinical picture found in COVID 19 patients 
regarding their airway secretions. ENaC and CFTR dysfunction 
in alveolar epithelial cells on the other hand have been linked 
to pulmonary edema due to reduced alveolar epithelial sodium 
and chloride absorption, required to establish the osmotic 
gradient for lung water absorption from the alveolar space 
through aquaporin channels and para-cellular pathways. CFTR 
is hereby a key regulator of alveolar liquid absorption. CFTR 
promoted liquid clearance in vitro and alveolar liquid clearance 
ex vivo (Matthay et  al., 2005; Mutlu et  al., 2005; Fang et  al., 
2006; Li et  al., 2012). Inflammation involving the cytokine 
TNF alpha can cause ENaC and CFTR and epi- and endothelial 
barrier dysfunction and is a dominant feature of COVID-19 
induced ARDS. TNF alpha production has been found to 
be  increased by action of the spike protein in the related 
SARS coronavirus 1 through shedding of the angiotensin 
converting enzyme-2 (ACE-2) ectodomain, a process which 
mediated subsequently by the cytoplasmic tail of ACE-2 activates 
the TNF alpha converting enzyme leading to increased TNF 
production (Haga et  al., 2008).
Keywords: tumor necrosis factor, conductance regulator chloride channel, epithelial sodium channel, 
Na(+)/K(+)/2Cl(−) cotransporter type 1 cystic fibrosis transmembrane, furosemide, acute respiratory distress syndrome, 
acute lung injury, pulmonary edema
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The Link Between TNF alpha and 
Excessive Lung Water
TNF alpha and the Cytoskeleton
The lung capillary endothelial and alveolar epithelial barrier 
function depends on the integrity of the cytoskeleton, components 
of which are actin-based microfilaments, microtubules, and 
intermediate filaments. TNF alpha induces endothelial actin 
microfilament disruption and intercellular gap formation that 
determine transcellular permeability. TNF alpha has been 
demonstrated to cause microtubule destabilization in human 
pulmonary artery endothelial cells (EC). TNF alpha hereby 
induced disassembly of the peripheral microtubule network. 
This is associated with TNF alpha–induced increases in 
permeability of EC layers (Petrache et  al., 2003).
TNF alpha induced microtubule re-arrangement together 
with an activation of EC contraction and permeability increase 
via G-protein coupled receptor mediated p38–mitogen-
activated protein kinase signaling and Rho-kinase activated 
phosphorylation of MLC phosphatase (MYPT1) leading to 
MYPT1 inactivation. This inhibition of phosphatase resulted 
in accumulation of diphospho-myosin light chains, which 
lead to acto-myosin polymerization, resulting in actomyosin 
contraction through stress fiber formation. This induced 
endothelial and epithelial cell contraction and therefore 
intercellular gap formation leading to permeability increase 
(Birukova et  al., 2004; Kása et  al., 2015).
TNF alpha and Pulmonary Ion Transport
We previously described in vivo the association of altered 
epithelial chloride transport in patients with reversible pulmonary 
edema associated with severe meningococcal septicemia, which 
like COVID 19 lung disease is characterized by a “cytokine 
storm” (Eisenhut et  al., 2006), which is also characterized by 
high levels of the pro-inflammatory cytokine TNF alpha (Van 
Deuren et  al., 1995).TNF alpha can inactivate ion transport 
draining alveolar and interstitial fluid as explained previously 
(Eisenhut and Wallace, 2011; Peteranderl et  al., 2017). Pointers 
toward the underlying mechanisms are that incubation of 
alveolar epithelial cells with TNF alpha (24 h) seemed to reduce 
epithelial sodium channel (ENaC) mRNA expression (Dagenais 
et al., 2004; Yamagata et al., 2009).  Epithelial sodium channels 
allow for build-up of the osmotic gradient of sodium absorbing 
alveolar liquid. TNF alpha reduced the expression of alpha, 
beta, and gamma-subunit mRNA of ENaC. TNF alpha treated 
cells displayed a reduction in alpha ENaC mRNA stability. 
In vivo studies in patients with meningococcal septicemia 
induced pulmonary edema however did not show a reduced 
sodium transport but features of an inactivation of the CFTR 
chloride channel, which is another essential prerequisite for 
removal of alveolar liquid by osmosis. This was in keeping 
with the previous in vitro data on the action of TNF alpha 
on CFTR chloride channels (Nakamura et  al., 1992)
In the colonic epithelium-derived tumor cell line (HT-29), 
it was established that TNF alpha reduced the stability of 
CFTR mRNA transcripts by a 35% shortening of its half-life. 
Future research needs to establish whether as demonstrated 
in influenza A virus induced pulmonary edema it is, in 
addition to a dysfunction of the epithelial sodium channel 
possibly not a reduction but an activation of the CFTR (Wolk 
et  al., 2008; Peteranderl et  al., 2017), which is key in the 
pathogenesis e.g., via chloride secretion into the airway drawing 
water by osmosis with it.
EVIDENCE TO SUPPORT THE 
HYPOTHESIS
TNF is central in the pathogenesis of inflammation and triggers 
the release of a multitude of inflammatory mediators including 
IL-1, IL-6, IL-8, and granulocyte/macrophage colony stimulating 
factor (GMCSF; Fiers, 1991; Szatmary, 1999), which have been 
found to be  elevated in COVID-19 lung disease. IL-1 itself, 
which has the potential to derange epi- and endothelial barrier 
integrity and alveolar ion transport similar to TNF (Eisenhut 
and Wallace, 2011), has not been found to be significantly 
higher in patients with more severe COVID 19 lung disease 
(Qin et  al., 2020). IL-6, IL-8, and GMCSF have not previously 
been directly linked to the pathogenesis of deranged ion transport 
in ARDS but there is limited evidence of the effects of IL-6  in 
reduction of endothelial barrier integrity in vitro and IL-8  in 
involvement of smoke inhalation induced lung injury in the 
rabbit model (Laffon et  al., 1999; Birukova et  al., 2016).
Early COVID 19 airway disease is characterized by dry, 
sticky airway secretions leading to collapse of lung segments 
(atelectasis) and a dry cough. This previously prompted 
research groups in China to set up a trial of acetylcysteine 
inhalation for mucolytic effect via the tracheal tube in intubated 
patients (now abandoned; Lythgoe and Middleton, 2020). 
This phenomenon is consistent with a reduction of CFTR 
mediated airway liquid film in CFTR dysfunction. Clinical, 
chest CT and pathological findings in COVID 19 lung disease 
are consistent with a combination of reduced airway liquid 
film causing tenacious airway secretions, atelectasis and 
consolidation, and pulmonary edema from reduced alveolar 
fluid clearance. Alveolar fluid clearance is impaired in 
inflammation related pulmonary edema and ARDS and 
fluid clearance is significantly lower in patients who die of 
ARDS (Ware and Matthay, 2001).
Risk Factors for COVID-19 Lung Disease
Advanced age and obesity have both been identified as risk 
factors for severe COVID-19 lung disease (Garg et  al., 2020; 
Toussie et al., 2020). Both have been associated with an increase 
in TNF alpha production (Huang et al., 2005; Kern et al., 2018)
TNF alpha and Coagulopathy
Injection of TNF into healthy volunteers induces a 
pro-coagulant state (Thijs et  al., 1993). The underlying 
mechanisms involve down-regulation of thrombomodulin at 
an endothelial level, reduction of tissue plasminogen and an 
increase in procoagulant factors like platelet activating factor 
and tissue plasminogen activator inhibitor (Aderka, 1991). 
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This may explain the pulmonary thrombosis discovered in 
COVID 19 lung disease as outlined above.
Direct Coronaviral Effects on ENaC and 
CFTR Function
Epithelial Sodium Channel
Previous in vitro studies of expression of the related 
SARS-coronavirus 1 proteins in Xenopus oocytes and human 
airway epithelial cells showed that co-expression of either SARS 
coronavirus 1 S or E protein alongside ENaC subunits significantly 
decreased amiloride-sensitive Na+ currents and γ-ENaC protein 
levels. S and E proteins acted through a reduction of ENaC 
exocytosis. Inhibition of PKCα/β1 and PKCζ restored the 
downregulation of ENaC activity by SARS. These results 
supported the hypothesis that pulmonary edema associated 
with SARS coronavirus 1 infection could be related to activation 
of protein kinase C (PKC) by SARS proteins which then 
decrease ENaC presence and activity on pulmonary epithelial 
cells (Ji et  al., 2009).
In addition, it is likely that double-strand RNA functioning 
as replicative intermediates during coronavirus infection 
(Hagemeijer et  al., 2012) are – like postulated in influenza 
and respiratory syncytial virus (RSV) lung disease – involved 
in ENaC dysfunction. It has been demonstrated in in vitro 
investigations for influenza virus and RSV that they can inhibit 
amiloride-sensitive sodium transport in cells of the respiratory 
tract. This effect was found to occur through nucleotide/P2Y 
purinergic receptors demonstrated by use of the synthetic 
double-stranded RNA analog poly-inosinic-cytidylic acid to 
be  probably mediated by double-strand RNA replication 
intermediates, which are TLR-3 ligands (Aeffner et  al., 2011). 
Cystic Fibrosis Transmembrane Conductance 
Regulator
A direct interaction of coronaviruses with CFTR has not 
been documented in vitro or in vivo but postulated from 
sequence data on several coronaviruses which revealed through 
alignments the main 3CL proteinase cleavage sites in 
polyproteins and this included some in the CFTR gene. This 
was obtained through use of a neural network able to recognize 
the cleavage sites in genomes (sensitivity 87.0%, specificity 
99.0%; Kiemer et  al., 2004).
EVIDENCE AGAINST THE HYPOTHESIS 
REGARDING TNF ALPHA AS THE KEY 
MEDIATOR CAUSING PULMONARY 
EDEMA IN COVID 19 LUNG DISEASE
Animal studies using the rat model of Pseudomonas aeruginosa 
lung disease demonstrated that TNF alpha has the potential 
to increase alveolar fluid clearance (Rezaiguia et  al., 1997), 
an effect which has been hypothesized to be  linked to the 
lectin-like domain of TNF, which was synthesized as TIP 
peptide (Yang et  al., 2010). The effect of this domain in the 
rat model was found to involve activation of the epithelial 
sodium channel in vitro: TIP peptide was shown to do this 
by binding to the carboxy-terminal domain of the α-subunit 
of the channel facilitating opening of the channel 
(Czikora et  al., 2014). This led to clinical trials in an attempt 
to improve alveolar fluid clearance using this synthetic TIP 
peptide (Aigner et  al., 2017; Krenn et  al., 2017). Experiments 
in the rat model in situ and ex vivo demonstrated that the 
effect of this lectin-like domain as a part of the complete 
TNF molecule is only active if the binding of TNF to its 
receptor TNFR1 is inhibited. The TNFR1 mediated reduction 
in alveolar fluid clearance, thus appears to outweigh the effects 
of the lectin-like domain (Braun et  al., 2005).
TESTING OF THE HYPOTHESIS
The role of a reduction in function of epithelial sodium and 
chloride transport could be  tested for chloride transport by 
analysis of chloride levels in exhaled breath condensate (EBC; 
Zacharasiewicz et  al., 2004) and levels correlated with TNF 
alpha concentrations.
To accomplish this task, fluid in the filter reservoir of the 
outgoing tubing of ventilators can be  analyzed for sodium and 
chloride levels compared to controls without pulmonary edema 
and corrected for dilution/evaporation by calculating the ratio 
to a reference molecule like urea: if the chloride levels are 
increased, a predominant hyperactivation of CFTR is likely 
involved and if levels are found to be  reduced, a reduction 
of CFTR function is likely. The same applies to conclusions 
for sodium levels on ENaC function. The possible involvement 
of TNF alpha can equally be  analyzed by measurement of 
TNF alpha in EBC via an ELISA and a negative correlation 
of chloride or sodium levels with TNF alpha levels would 
confirm an involvement in CFTR or ENaC dysfunction.
IMPLICATIONS OF A CONFIRMATION 
OF THE HYPOTHESIS
Potential Avenues for Treatment and 
Prevention
Anti-TNF alpha Treatments
The coronavirus mouse model demonstrated that the TNF 
alpha pathway is a key in the pathogenesis of systemic 
murine coronavirus disease: infection with SARS-CoV 1 of 
double-null TNF alpharsf1a/1b−/− mice showed that the 
mouse strain used had a reduced weight loss, indicating 
that TNF alpha may promote pathogenesis in SARS-CoV 1 
disease mediated by TNF alpha receptors (McDermott et  al., 
2016). Administration of anti-TNF alpha antibodies reduced 
weight loss and increased survival in a SARS-CoV 1 pneumonia 
mouse model (Channappanavar et  al., 2016). We  support 
the appeal by others for anti-tumor necrosis factor therapies 
for COVID-19 (Feldmann et  al., 2020).
Implementation of anti-TNF alpha therapies in patients with 
ARDS may be  too late as the cell barriers and ion transport 
systems may already be  irreparably disrupted. Prevention of 
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TNF alpha production in patients at risk may prevent hospital 
admission and deterioration of infected patients at risk of 
ARDS from this infection.
Two systematic reviews of randomized placebo controlled 
trials revealed anti-TNF antibody therapies as used to treat 
auto-immune diseases have been associated with a significantly 
increased risk of infections ranging from 20 (any infection) 
to 250% (tuberculosis; Minozzi et al., 2016). In another systematic 
review, the number needed to harm from serious infections 
(infection that requires antimicrobial therapy and/or 
hospitalization) was 59 (95% confidence interval (CI), 39–125) 
and a pooled odds ratio (OR) for malignancy was 3.3 [95% 
CI, 1.2–9.1] with a number needed to generate one additional 
malignancy 154 (95% CI, 91–500) within a treatment period 
of 6–12  months (Bongartz et  al., 2006). This highlights the 
need to develop strategies that preferentially blunt the deleterious 
but not the positive actions of the cytokine against infections 
and malignancies.
In the following, we  are exploring preventative options, 
which could reduce TNF alpha production without the adverse 
effects on infection rates and malignancy observed with anti-TNF 
antibody therapies.
Steroids
Steroids suppress cytokine production, including TNF alpha 
but have significant adverse effects which may outweigh 
any benefit; there are no published prospective double 
blind randomized controlled trials (RCT) on steroid in 
COVID 19 lung disease but a meta-analysis of 15 mainly 
retrospective cohort and studies using historical controls 
showed that in 5,270 patients analyzed corticosteroid 
treatment was associated with higher mortality (RR = 2.11; 
95% CI  =  1.13–3.94) possibly related to a higher rate of 
bacterial infection and hypokalemia (Yang et  al., 2020). 
This lack of an effect is likely due to use after the effects 
of TNF alpha on tissues is already established in patients 
in the intensive care unit. However, this meta-analysis 
should be interpreted with caution because a high mortality 
rate shown in corticosteroid-treated group in SARS and 
Middle East respiratory syndrome (MERS) could be  due 
to more systemic compromise evident from baseline 
characteristics (e.g., older age, higher rate of comorbid 
conditions, and severe patients) in most individual studies.
Statins
Animal model data showed that reduction of inflammation 
as mediated by NF-kappaB in SARS coronavirus-infected mice 
increased survival (DeDiego et  al., 2014) and atorvastatin 
attenuated TLR4-mediated NF-kappaB activation (Chansrichavala 
et  al., 2009). To asses this potential, which would apply to 
COVID 19 lung disease, it is important to look at evidence 
from treatment of conditions leading to activation of NF-kappaB 
like bacterial infections and then ALI/ARDS by statins. In 
a double blind randomized controlled trial, the administration 
of simvastatin in bacterial infections was investigated. Enrolled 
were a total of 83 patients and 42 patients received simvastatin 
and 41 received placebos. In the simvastatin group, TNF 
alpha and IL-6 levels were reduced (Novack et  al., 2009). 
In animal studies (mice), simvastatin attenuated vascular leak 
and inflammation in inflammatory lung injury in mice 
(Jacobson et  al., 2005). If administered in already present 
acute lung injury (ALI) statin administration in humans did 
not alter the outcome with regard to organ failures (Kor 
et  al., 2009) in one study. A subsequent systematic review 
and meta-analysis of both randomized clinical trials and 
cohort studies, which included a total of 12 studies (eight 
cohort studies and four randomized controlled trials with a 
total of 9,309 patients), which did not analyze the effects 
of statin use commenced only during ALI/ARDS management 
separately, found that the sepsis-related organ failure assessment 
(SOFA) was significantly lower in patients receiving statins 
and the number of ventilator-free days was increased among 
statin users (Feng, 2018). A recent re-analysis of one randomised 
controlled trial (RCT) using statins as an intervention to 
treat ALI/ARD, which was included in this meta-analysis, 
focused on a subgroup of patients with higher inflammatory 
markers. This included higher values of sTNRr-1 and IL-6 
levels. The hyper-inflammatory subphenotype had fewer 
ventilator-free days. As opposed to the result of the original 
trial report, which did not identify a difference in 28-day 
survival between simvastatin and placebo, this analysis 
comparing subjects in a hypo-inflammatory and hyper-
inflammatory subphenotype found that within the hyper-
inflammatory subphenotype simvastatin treated patients had 
a significantly reduced 28- and 90-day mortality (p  =  0.008). 
The mortality was 32% in the hyper-inflammatory subphenotype 
treated with simvastatin in comparison to 45% in the placebo 
group with this subphenotype (Calfee et  al., 2018).
Analysis of a prospective cohort study in 575 critically ill 
patients those on statin therapy prior to hospitalization had 
a reduced probability of developing ALI/ARDS (OR, 0.60; 95% 
CI, 0.36–0.99; O’Neal et  al., 2011).
In a 3-year prospective analysis of data 11,490 patients 
with atherosclerotic diseases, a comparison of two groups- 
those receiving statins in the final month of follow-up and 
those who did not receive statins revealed the following: 
compared to the control group, the risk of infection-related 
mortality was significantly lower in the statin group [0.9% 
vs. 4.1%, relative risk of 0.22 (95% CI, 0.17–0.28)]. This 
result remained highly significant in a survival analysis, 
which took potential confounders into account and used a 
propensity score for receiving statins (hazard ratio, 0.37; 
95% CI, 0.27–0.52; Almog et  al., 2007).
Aspirin
Aspirin reduces inflammatory mediator production, including 
TNF alpha and IL-6 (Loesche et al., 2012). Erlich et al. (2011) 
investigated the association of prehospital aspirin therapy and 
ALI/ARDS. Included were 161 patients with at least one major 
risk factor for ALI/ARDS. Therapy with aspirin on admission 
was associated with a significantly lower rate of ALI/ARDS 
when compared to patients without aspirin (17.7% vs. 28.0%; 
OR, 0.37; 95% CI, 0.16–0.84). The authors reported that the 
benefit of aspirin therapy remained significant after adjusting 
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for smoking and pre-hospital statin use but not for coronary 
heart disease, which was more common in the group using 
aspirin (Erlich et  al., 2011). In another observational study 
on the association of pre-hospital aspirin therapy and ALI/ARDS 
(Kor et  al., 2011) on 3,855 patients out of which 25% were 
receiving aspirin at the time of hospitalization patients with 
aspirin were more severely affected as evident from higher 
APACHEII scores [12 (8–16) vs. 9 (5–14)]. There was a lower 
incidence of ALI/ARDS in patients on aspirin (OR, 0.65; 95% 
CI, 0.46–0.90). In another such study, pre-hospital use of both 
statins and aspirin was associated with the lowest rates of 
ALI/ARDS and mortality (O’Neal et al., 2011). Future research 
in COVID-19 lung disease needs to establish whether a 
reduction in pulmonary vascular thrombosis is involved in 
this aspirin effect.
Curcumin
Curcumin reduces TNF alpha production through epigenetic 
modulation of TNF alpha producing mononuclear blood cells 
(Sahebkar et  al., 2016; Hassan et  al., 2019). In a meta-analysis 
including eight RCTs, the results demonstrated a significant 
reduction of circulating TNF alpha levels following curcumin 
administration (WMD, −4.69  pg/ml; 95% CI, −7.10, −2.28; 
p  <  0.001). This effect size was robust in sensitivity analysis.
Curcumin and CFTR
CFTR function can be enhanced by curcumin (Becq et al., 2011). 
Curcumin hereby facilitates the release of F508-CFTR from 
the endoplasmic reticulum, thus aiding integration in the plasma 
membrane. After integration, it enhances channel activity. This 
appears to be  related to the disintegration of the calnexin-
F508-CFTR complex and a stabilizing effect on the tertiary 
structure of F508-CFTR.
The fact that unencapsulated curcumin is hardly absorbed 
makes it necessary to use nanoparticle preparations like those 
encapsulated in poly lactic-co-glycolic acid nanoparticles.
Phosphodiesterase 5 Inhibitors
Trials in human CF nasal epithelial and baby hamster 
kidney (BHK) cells and mouse experiments showed that the 
phosphodiesterase 5 (PDE5) inhibitor sildenafil restored F508del-
CFTR activity and activated chloride transport on nasal potential 
difference measurement in mice in vivo. In another mouse 
strain, it was associated with an improved CFTR-mediated 
current attributable to a reduction of an excessive 
proinflammatory response (Becq et  al., 2011).
Ivacaftor
Ivacaftor can hold the channel structure of CFTR open, thus 
facilitating chloride flow. This then normalizes the amount 
of fluid at the surface of the cell. Ivacaftor significantly 
enhanced pulmonary fluid clearance in isolated pig lung 
lobes. In a model using model elevated hydrostatic pressure 
induced pulmonary edema, which resulted in decreased CFTR 
activity and liquid absorption, ivacaftor partially reversed 
this pathology (Li et  al., 2017).
Vitamin D
As reviewed recently (Greiller and Martineau, 2015), vitamin 
D has through the induction of an increased production of 
anti-microbial peptides LL-37 and beta-defensin-2 in monocytes 
broad spectrum anti-viral effects.
With regard to coronaviruses, vitamin D induced beta 
defensin 2 promoted antiviral immunity in vitro and in vivo. 
This was demonstrated by means of a receptor-binding domain 
(RBD) of Middle East respiratory syndrome-coronavirus (MERS-
CoV) spike protein (S RBD). When HBD 2-conjugated S RBD 
was incubated with THP-1 human monocytic cells, the expression 
of IFN-β, IFN-γ, MxA, PKR, and RNaseL molecules was 
increased compared to controls (Kim et  al., 2018).
In addition, it has immunomodulatory effects reducing TNF 
alpha production. In alveolar A549 cells, influenza infection 
increased the production of pro-inflammatory cytokines and 
chemokines and the addition of vitamin D either before or 
after influenza infection reduced gene expression of among 
other cytokines TNF alpha and IL-6.
Most of the numerous observational studies on the association 
between vitamin D status and acute respiratory tract infections 
(RTI) showed independent associations between low vitamin 
D status and increased risk of acute viral respiratory tract 
infections. (Greiller and Martineau, 2015). A meta-analysis of 
11-placebo controlled studies using vitamin D for the prevention 
of RTI (n  =  5,660) demonstrated a protective effect against 
RTI (OR, 0.64; 95% CI, 0.49–0.84; Bergman et  al., 2013).
With regard to effects of vitamin D on the severity of 
ARDS, there are two low quality retrospective cohort studies 
and both show an association of low vitamin D levels with 
more severe ARDS of a variety of causes: in 1985, critically 
ill adults patients with 25(OH)D levels lower than 30  mg/
ml had a significantly higher risk of acute respiratory failure 
(Thickett et  al., 2015). In another study, which included 
52 patients with ARDS, 57 patients who had esophagectomy 
(at risk of ARDS) and 8 patients who had esophagectomy 
with high-dose vitamin D supplementation prior to surgery, 
the odds of ARDS in patients with 25(OH)D3  <  20  nmol/L 
was 3.5-fold higher than that of patients with 25(OH)
D3  ≥  20  nmol/L [OR  =  3.5 (95% CI, 1.06–11.6; p  =  0.040)]. 
After adjustment for age, gender, diagnostic category, staging, 
and degree of cigarette consumption, patients with 25(OH)
D3  <  20  nmol/L show a significantly higher odds of ARDS 
compared to patients with 25(OH)D > 20 nmol/L [OR = 4.2 
(95% CI, 1.13–15.9; p  =  0.032)]. On logistic regression 
analysis, 1  nmol/L increments of 25(OH)D were associated 
with reduction in odds of ARDS by 17% for every 1 nmol/L. 
On admission to ITU lower plasma 1, 25(OH)2D levels 
were found in patients who died compared to survivors 
(Dancer et  al., 2015).
Treatment of Established ARDS With NKCC1 
Inhibitors
In pulmonary edema caused by inflammation, ENaC inhibition 
generates a gradient for Na+ influx due to lowered intracellular 
sodium concentrations. This influx is regulated by the 
basolateral Na(+)/K(+)/2Cl(−) cotransporter type 1(NKCC1) 
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in alveolar type 1 epithelial cells. Cl− enters in cotransport 
with Na+, and can leave the cell along an electrochemical 
gradient on the apical side through CFTR, resulting in 
Cl−-driven fluid secretion and subsequently alveolar liquid 
accumulation as seen in pulmonary edema and ARDS 
(Weidenfeld and Kuebler, 2017), and TNF alpha upregulates 
NKCC1 mRNA and protein levels. In the largest (n  =  1,000) 
and highest quality randomized controlled trial comparing 
conservative with liberal fluid management in ARDS, on 
which current fluid management guidelines globally are based, 
patients in the conservative arm of the study received 
significantly more often (133/497 vs. 312/503) and higher 
(74 vs. 148  mg/day) daily doses of furosemide which is an 
inhibitor of the NKCC1 (National Heart, Lung, and Blood 
Institute Acute Respiratory Distress Syndrome (ARDS) Clinical 
Trials Network et  al., 2006). NKCC1 inhibition may have 
made the crucial difference in outcome including that it was 
associated with more ventilator-free days (14.6  ±  0.5 vs. 
12.1  ±  0.5, p  <  0.001) and days outside the intensive care 
unit (13.4 ± 0.4 vs. 11.2 ± 0.4, p < 0.001) in this “conservative” 
treatment group. This is supported by recent experimental 
data (Shen et al., 2018). Despite an approval of the conservative 
fluid management strategy, recent guidelines on COVID 19 
induced ARDS management (Alhazzani et  al., 2020; Matthay 
et  al., 2020) do not mention furosemide or other NKCC1 
inhibitors like bumetanide. It appears to be  regarded as 
sufficient to just drain a certain amount of fluid from the 
patient by measures including hemodialysis. This ignores the 
specific potentially beneficial effect of alveolar epithelial NKCC1 
inhibition by furosemide and other loop diuretics on lung 
fluid clearance and needs to be  immediately addressed by 
randomized controlled trials.
CONCLUSION
Strategies for prevention of COVID 19 lung disease in vulnerable 
groups need to consider vitamin D, aspirin, statins, and curcumin 
as primary prevention of the potentially fatal hyperinflammatory 
state leading to acute lung injury, ARDS, and multi-organ 
failure for all members of those groups and vitamin D for 
the population as a whole.
For treatment of established acute lung injury or ARDS 
due to COVID 19, NKCC1 inhibitors, anti-TNF alpha treatment, 
aspirin, and statins need to be included in prospective randomized 
placebo controlled trials.
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